GSK Announces Inclusion of Innovative COPD Treatment ANORO® (Umeclidinium/Vilanterol) in China's 2019 National Reimbursement Drug List
GSK
Pharmaceutical R&D Manufacturer
Beijing, November 28, 2019 /PRNewswire/ -- GlaxoSmithKline (GSK) announced today that its dual bronchodilator Anoro Ellipta (generic name: umeclidinium/vilanterol inhalation powder), used for the treatment of chronic obstructive pulmonary disease (COPD), has been officially included in the "2019 National Reimbursement Drug List."
Latest data show that nearly 100 million people in China are affected by chronic obstructive pulmonary disease (COPD), with a significant increase in prevalence in recent years; the prevalence among individuals aged 40 and above has risen from 8.2% in 2002 to 13.7%.[1],[2]Due to low awareness and diagnosis rates, chronic obstructive pulmonary disease (COPD) has become the third leading cause of death among Chinese residents, posing significant challenges to China's public health and medical system.[3]。
Anoro Ellipta, the first dual bronchodilator launched in China, is the first and only dual bronchodilator proven in head-to-head studies to provide greater improvements in lung function and quality of life compared to existing bronchodilators.[4]-[10]. Oretivir is currently widely recognized internationally, having been approved for marketing in 98 countries and regions and included in the national reimbursement drug lists of 47 countries and regions.
In addition to the first-time inclusion of Anoro Ellipta in the National Reimbursement Drug List, GSK’s other first-line antidepressant, Seroxat CR, has also successfully renewed its contract, continuing to benefit more patients with depression.
Fabio Landazabal, Senior Vice President for Emerging Markets at GSK, stated, “Driven by the Chinese government’s proactive healthcare reform policies, not only has the review and approval process for innovative drugs accelerated, but we have also observed the government expediting the inclusion of these medicines in the national reimbursement drug list. The successful inclusion of Anoro Ellipta in the national reimbursement list is the result of concerted efforts by multiple stakeholders and reaffirms GSK’s unwavering commitment to being rooted in China, partnering with China, and serving China. We will continue to support the Chinese government’s healthcare reform policies, uphold our innovation-driven and patient-centric values, and constantly improve the accessibility and affordability of innovative medicines, thereby contributing to the realization of the ‘Healthy China 2030’ vision.”
Mr. Wang Xinguang, Vice President of Corporate Affairs, Market Access, and Commercial Operations at GSK, stated: “The Chinese government has been vigorously supporting the inclusion of innovative medicines in the National Reimbursement Drug List (NRDL). It is highly encouraging that GSK’s innovative products have been included in the NRDL. For patients, accessing the most innovative and cost-effective medicines in the shortest possible time has long been their expectation; for enterprises, driven by national reimbursement policies, expanding the accessibility of our medicines to benefit more patients remains our unwavering commitment. Going forward, GSK will continue to work closely with the Chinese government to ensure that more patients in China benefit from our innovative medicines.”
AboutGSK：
GSK is a science-led global healthcare company dedicated to helping people do more, feel better, and live longer, thereby improving the quality of human life. For more information, please visitwww.gsk.com。
References:
[1]. Zhong N, et al. Am J Respir Crit Care Med. 2007;176(8):753-760.
[2]. Wang C. et al. The Lancet 2018; 391 (10131).
[3]. Zhou M, et al. Lancet. 2019 Jun 24. pii S0140-6736(19)30427-1.
[4]. Feldman G, et al. Int J COPD. 2016;11:719–730;
[5]. Rheault T, et al. ERJ Open Res. 2016;2:00101-2015;
[6]. Lipson DA, et al. N Engl J Med. 2018;378:1671–1680;
[7]. Maleki-Yazdi MR, et al. Respir Med. 2014;108:1752–1760;
[8]. Feldman GJ, et al. Adv Ther. 2017;34:2518–2533;
[9]. Donohue JF, et al. Respir Med. 2015;109:870–881;
[10]. Bevespi aerosphere EPAR Public Assessment Report. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/bevespi-aerosphere. Accessed May 2019.